These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The induction of ovulation with pulsatile gonadotrophin-releasing hormone (GnRH) administration in hyperandrogenic women after down-regulation with buserelin or suppression with an oral contraceptive. Gerhard I; Matthes J; Runnebaum B Hum Reprod; 1993 Dec; 8(12):2033-8. PubMed ID: 8150899 [TBL] [Abstract][Full Text] [Related]
29. Ovarian hyperstimulation associated with the sole use of leuprolide for ovarian suppression. Yeh J; Barbieri RL; Ravnikar VA J In Vitro Fert Embryo Transf; 1989 Aug; 6(4):261-3. PubMed ID: 2515236 [TBL] [Abstract][Full Text] [Related]
30. [Gonadotropin-releasing hormone (GnRH) and its analogs in current medicine]. Karck U; Neulen J; Wieacker P; Breckwoldt M Med Klin (Munich); 1992 Feb; 87(2):87-93. PubMed ID: 1542289 [No Abstract] [Full Text] [Related]
31. Management of pituitary gonadal function via gonadotrophin releasing hormone (GnRH) antagonists, including ovulation induction by co-administration of either gonadotrophins or pulsatile GnRH. Gordon K; Irianni F; Hodgen GD Hum Reprod; 1993 Nov; 8 Suppl 2():204-9. PubMed ID: 8276963 [TBL] [Abstract][Full Text] [Related]
32. Sonographic monitoring of ovarian volume during LHRH analogue therapy in women with polycystic ovarian syndrome. Jaffe R; Abramowicz J; Eckstein N; Vagman I; Fejgin M; Ayalon D J Ultrasound Med; 1988 Apr; 7(4):203-6. PubMed ID: 2966864 [TBL] [Abstract][Full Text] [Related]
33. Menses predict successful ovarian down-regulation using GnRH-a prior to IVF-ET. Kavic S; Sauer MV; Lindheim SR J Assist Reprod Genet; 2000 May; 17(5):296-8. PubMed ID: 10976418 [No Abstract] [Full Text] [Related]
35. The duration of pituitary suppression by means of intranasal gonadotropin hormone-releasing hormone analogue administration does not influence the ovarian response to gonadotropin stimulation and success rate in a gamete intrafallopian transfer (GIFT) program. Remorgida V; Anserini P; Croce S; Costa M; Ferraiolo A; Centonze A; Gaggero G; Capitanio GL J In Vitro Fert Embryo Transf; 1989 Apr; 6(2):76-80. PubMed ID: 2498446 [TBL] [Abstract][Full Text] [Related]
36. The duration of leuprolide acetate administration prior to ovulation induction does not impact ovarian responsiveness to exogenous gonadotropins. Scott RT; Neal GS; Illions EH; Hayslip CA; Hofmann GE Fertil Steril; 1993 Aug; 60(2):247-53. PubMed ID: 8339819 [TBL] [Abstract][Full Text] [Related]
37. Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Emons G; Ortmann O; Pahwa GS; Hackenberg R; Oberheuser F; Schulz KD Acta Obstet Gynecol Scand Suppl; 1992; 155():31-8. PubMed ID: 1386955 [TBL] [Abstract][Full Text] [Related]
38. Species differences in the sensitivity to GnRH analogs. Thau RB; Limonta P; Schmidt F; Sundaram K J Steroid Biochem; 1985 Nov; 23(5B):811-7. PubMed ID: 3935866 [TBL] [Abstract][Full Text] [Related]
39. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Badawy A; Goda H; Ragab A Reprod Biomed Online; 2007 Aug; 15(2):215-9. PubMed ID: 17697500 [TBL] [Abstract][Full Text] [Related]
40. Indications for GnRH agonists in an in vitro fertilization program. Diedrich K; Schmutzler R Ann N Y Acad Sci; 1991; 626():228-37. PubMed ID: 1905508 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]